Eusol Biotech Co.,Ltd. (TPEX:6652)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
1.960
0.00 (0.00%)
Apr 9, 2026, 2:59 PM CST
Market Cap268.52M -75.3%
Revenue (ttm)2.08M
Net Income-40.42M
EPS-0.30
Shares Out 137.00M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume7,488,893
Open2.250
Previous Close1.960
Day's Range1.870 - 2.280
52-Week Range1.870 - 10.200
Beta-0.08
Analystsn/a
Price Targetn/a
Earnings DateAug 7, 2026

About Eusol Biotech

Eusol Biotech Co.,Ltd. focuses on research and development of new drugs for the treatment of nerve injuries in Hong Kong and Taiwan. The company’s pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for spinal cord injury that is in phase 1, 2, and 3 clinical trials, and SM-1, a 3-in-1 combination sleeping aid. It also offers small molecule drugs including EPS221, a selective serotonin reuptake inhibitor; EPS222, a calcium channel blocker for cardiovascular disease; EPS251, a drug for rheumatology/anti-inflamma... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1994
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6652
Full Company Profile

Financial Performance

Financial Statements